プログラム委員会
-
Yuko Kojima, RPH Sr. Executive Director
Eli Lilly Japan K.K., Japan -
Keiko Tsumori, MSC Associate Principle Scientist, Medical Writing, Regulatory Affairs Area, Japan D
MSD K.K., Japan -
Rika Abe, RPH Research Administrator, Office of the Fugaku Society 5.0 Initiative
RIKEN Center for Computational Science, Japan -
Eiji Kurosaki
Japan -
Hiroki Nagahama, MS Director, Japan Safety Risk Management Lead, Clinical Safety & Pharmacovigilance
GlaxoSmithKline K.K., Japan -
Shohko Sekine Reviewer, Office of New Drug IV
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Seiki Yamazaki Director, Clinical Informatics & Innovation
Pfizer Japan Inc., Japan -
Hideo Nakada, RPH Deputy Associate Manager, Department of Hospital Pharmacy
Keio University, Japan
